This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—In 1983, clinical research done by me and histopathologic studies done by David Apple, MD, identified the abnormally high complication rate of the IOLAB Azar 91Z intraocular lens.1 The January 1987 issue of the Archives reported complications of the Azar 91Z and other members of the family of semiflexible, closed-loop anterior chamber intraocular lenses.2-4 I believe that additional elaboration is needed on the obligation to inform and follow up patients who have these complication-prone lenses in their eyes. These obligations, in my opinion, extend not only to surgeons but also to institutional review committees, physician lens designers and advocates, lens manufacturers, and the Food and Drug Administration (FDA). This subject is virtually absent from the ophthalmic literature.No published study has demonstrated a leveling off of the complication rate with these lenses. As length of follow-up increases so does the complication rate.4,5 All patients
Hagan JC. Physician Obligations Regarding Semiflexible, Closed-Loop Anterior Chamber Lenses. Arch Ophthalmol. 1987;105(6):744-745. doi:10.1001/archopht.1987.01060060022012